Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943693 · ClinicalTrials.gov registry record · Early Phase 1
Dual Versus Single Shock for Cardioversion of Atrial Fibrillation
A Early Phase 1 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03943693: Clinical Trial Early Phase 1 study, sponsored by University of Oklahoma.
NCT03943693 is a Early Phase 1 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943693, a Early Phase 1 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The investigators aim to investigate the immediate success rate (rate of termination of atrial fibrillation) of dual shock cardioversion compared with standard single shock cardioversion in patients with baseline characteristics adversely influencing successful cardioversion. Baseline characteristics known to reduce the success rate of single shock cardioversion include: increased body mass index (BMI), chronic obstructive pulmonary disease, sleep apnea, enlarged left atrium, longer duration of atrial fibrillation and use of amiodarone.
Primary Outcome
Successful termination of atrial fibrillation after initial DCCV. Successful = cardioversion = immediate termination of atrial fibrillation
Interventions
- DEVICE Double shock
- DEVICE Single shock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-05-31 |
| Phase | Early Phase 1 |
Why NCT03943693 stopped before completion
NCT03943693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Double shock is the first listed.
NCT03943693 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03943693 about?
NCT03943693 is a clinical study titled "Dual Versus Single Shock for Cardioversion of Atrial Fibrillation". The investigators aim to investigate the immediate success rate (rate of termination of atrial fibrillation) of dual shock cardioversion compared with standard single shock cardioversion in patients with baseline characteristics adversely influencing successful cardioversion. Baseline characteristic...
What is the current status of trial NCT03943693?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-04-01. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT03943693?
The interventions under investigation include: Double shock (DEVICE), Single shock (DEVICE).
Who is sponsoring clinical trial NCT03943693?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03943693's enrollment target sits among peer trials
5 1887th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI